Merck: Erbitux Phase III Study - FLEX Increases Overall Survival In First-line Treatment Of Non-Small Cell Lung Cancer
Merck KGaA announced that Erbitux® (cetuximab) combined with vinorelbine plus cisplatin met the primary endpoint of increasing overall survival compared with chemotherapy alone in a Phase III study initiated by Merck Serono in patients with advanced non-small cell lung cancer (NSCLC).
